Recent Results In Phosphodiesterase Inhibitor Development and CNS Applications

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

Abstract

Phosphodiesterase inhibitor discovery is an established area of research that continues to develop in concert with biological efforts to identify new potential applications for this target family. Selected phosphodiesterase enzymes are established targets for treatment of erectile dysfunction (PDE5) and for various pulmonary and cardiovascular disorders (PDE3 and PDE4). This chapter details recent advances in the development of new selective and potent PDE inhibitors and discuss future applications of these compounds for the treatment of psychiatric and neurological disorders.

Original languageEnglish
Title of host publicationCyclic-Nucleotide Phosphodiesterases in the Central Nervous System
Subtitle of host publicationFrom Biology to Drug Discovery
PublisherWiley Blackwell
Pages115-144
Number of pages30
ISBN (Electronic)9781118836507
ISBN (Print)9780470566688
DOIs
StatePublished - 28 Apr 2014

Fingerprint

Phosphodiesterase Inhibitors
Phosphoric Diester Hydrolases
Erectile Dysfunction
Nervous System Diseases
Psychiatry
Lung
Enzymes
Research

Keywords

  • Assays
  • Chemotypes
  • Drug discovery
  • Medicinal chemistry

Cite this

Rotella, D. (2014). Recent Results In Phosphodiesterase Inhibitor Development and CNS Applications. In Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System: From Biology to Drug Discovery (pp. 115-144). Wiley Blackwell. https://doi.org/10.1002/9781118836507.ch05
Rotella, David. / Recent Results In Phosphodiesterase Inhibitor Development and CNS Applications. Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System: From Biology to Drug Discovery. Wiley Blackwell, 2014. pp. 115-144
@inbook{442cc5d314544a759b64394005ac55b9,
title = "Recent Results In Phosphodiesterase Inhibitor Development and CNS Applications",
abstract = "Phosphodiesterase inhibitor discovery is an established area of research that continues to develop in concert with biological efforts to identify new potential applications for this target family. Selected phosphodiesterase enzymes are established targets for treatment of erectile dysfunction (PDE5) and for various pulmonary and cardiovascular disorders (PDE3 and PDE4). This chapter details recent advances in the development of new selective and potent PDE inhibitors and discuss future applications of these compounds for the treatment of psychiatric and neurological disorders.",
keywords = "Assays, Chemotypes, Drug discovery, Medicinal chemistry",
author = "David Rotella",
year = "2014",
month = "4",
day = "28",
doi = "10.1002/9781118836507.ch05",
language = "English",
isbn = "9780470566688",
pages = "115--144",
booktitle = "Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System",
publisher = "Wiley Blackwell",

}

Rotella, D 2014, Recent Results In Phosphodiesterase Inhibitor Development and CNS Applications. in Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System: From Biology to Drug Discovery. Wiley Blackwell, pp. 115-144. https://doi.org/10.1002/9781118836507.ch05

Recent Results In Phosphodiesterase Inhibitor Development and CNS Applications. / Rotella, David.

Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System: From Biology to Drug Discovery. Wiley Blackwell, 2014. p. 115-144.

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

TY - CHAP

T1 - Recent Results In Phosphodiesterase Inhibitor Development and CNS Applications

AU - Rotella, David

PY - 2014/4/28

Y1 - 2014/4/28

N2 - Phosphodiesterase inhibitor discovery is an established area of research that continues to develop in concert with biological efforts to identify new potential applications for this target family. Selected phosphodiesterase enzymes are established targets for treatment of erectile dysfunction (PDE5) and for various pulmonary and cardiovascular disorders (PDE3 and PDE4). This chapter details recent advances in the development of new selective and potent PDE inhibitors and discuss future applications of these compounds for the treatment of psychiatric and neurological disorders.

AB - Phosphodiesterase inhibitor discovery is an established area of research that continues to develop in concert with biological efforts to identify new potential applications for this target family. Selected phosphodiesterase enzymes are established targets for treatment of erectile dysfunction (PDE5) and for various pulmonary and cardiovascular disorders (PDE3 and PDE4). This chapter details recent advances in the development of new selective and potent PDE inhibitors and discuss future applications of these compounds for the treatment of psychiatric and neurological disorders.

KW - Assays

KW - Chemotypes

KW - Drug discovery

KW - Medicinal chemistry

UR - http://www.scopus.com/inward/record.url?scp=84926086998&partnerID=8YFLogxK

U2 - 10.1002/9781118836507.ch05

DO - 10.1002/9781118836507.ch05

M3 - Chapter

SN - 9780470566688

SP - 115

EP - 144

BT - Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System

PB - Wiley Blackwell

ER -

Rotella D. Recent Results In Phosphodiesterase Inhibitor Development and CNS Applications. In Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System: From Biology to Drug Discovery. Wiley Blackwell. 2014. p. 115-144 https://doi.org/10.1002/9781118836507.ch05